Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Dividend Kings to Buy in 2026. CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says On January 16, Johnson & Johnson (NYSE:JNJ) shared results from a new analysis of Phase 3 data showing that CAPLYTA (lumateperone), when used alongside an antidepressant, delivered significantly higher remission rates in adults with major depressive disorder compared with placebo plus an antidepressant after six weeks. The company also said the b ...